Research ArticleOriginal Article
Open Access

Comparative effectiveness of dual antiplatelet therapy versus monotherapy in patients with ischemic stroke

Rahmah A. Algarni, Abdulhamid A. Althagafi, Samah Alshehri, Mohannad Alshibani and Omar Alshargi
Neurosciences Journal October 2023, 28 (4) 220-226; DOI: https://doi.org/10.17712/nsj.2023.4.20230021

Article Figures & Data

Figures

  • Figure 1
    Figure 1

    - Cumulative survival probability according to time (months) to recurrence of ischemic stroke for the groups of patients who received aspirin-clopidogrel dual antiplatelet therapy (DAPT) and monotherapy (aspirin or clopidogrel).

  • Figure 2
    Figure 2

    - Kaplan-Meier survival function for comparison of month to rehospitalization between the groups of patients who received aspirin-clopidogrel dual antiplatelet therapy (DAPT) and monotherapy (aspirin or clopidogrel) for the management of ischemic stroke.

  • Figure 3
    Figure 3

    - Cumulative survival probability according to time (months) to all-cause mortality for the groups of patients who received aspirin-clopidogrel dual antiplatelet therapy (DAPT) and monotherapy (aspirin or clopidogrel) for the management of ischemic stroke.

Tables

  • Table 1

    - Demographic and clinical characteristics of the patients.

    VariablesAM Group (n=173)DAPT Group (n=178)P-value
    Age (years)62 (±13.0)63 (±14.0)0.457
    Gender, n (%)
    Male119 (52)110 (48)0.170
    Risk factor, n (%)
    Hypertension127 (52)119 (48)0.180
    Diabetes mellitus107 (50)106 (50)0.660
    Chronic kidney disease8 (40)12 (60)0.390
    Ischemic heart disease33 (70)14 (30)<0.001
    Dyslipidemia19 (49)20 (51)0.940
    Cancer1 (17)5 (83)0.110
    Hepatic diseases1 (50)1 (50)0.980
    Heart failure7 (54)6 (46)0.740
    Smoking status18 (44)23 (56)0.460
    Dosing
    Aspirin81mg--
    Clopidogrel75mg--
    Aspirin + Clopidogrel-81mg + 75mg-

    • AM - Antiplatelets therapy with Aspirin or Clopidogrel, DAPT - Dual Antiplatelet therapy with Aspirin + Clopidogrel

  • Table 2

    - Cox proportional hazard analysis for comparison of the recurrence of ischemic stroke between the dual antiplatelet therapy and monotherapy groups after adjusting for baseline covariates.

    CovariateStroke recurrenceHazard ratio (95% confidence interval)P-value
    DAPTAM
    Hypertension141012.23 (0.95–15.12)0.060
    Diabetes mellitus1270.41 (0.07–2.36)0.320
    Dyslipidemia132.33 (0.41–13.33)0.340
    Ischemic heart disease350.42 (0.06–3.00)0.380
    Heavy smocking410.18 (0.01–3.07)0.230

    • DAPT - Dual Antiplatelet Therapy with Aspirin + Clopidogrel, AM - Antiplatelet Monotherapy with Aspirin or Clopidogrel

Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools
Bookmark this article

Jump to section